The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder
Autor: | Taylor Vega, Catriona S. Miller, Allison R. Coker, Jennifer M. Mitchell, Dawn Weinstein, Andrew S. Kayser |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
AUD Alcohol use disorder Pharmacology Medical and Health Sciences Choice Behavior Alcohol Use and Health Substance Misuse 0302 clinical medicine Psychiatry Cross-Over Studies Alcoholism 6.1 Pharmaceuticals Mental health Female medicine.symptom Alcohol consumption medicine.drug Adult Impulsivity Alcohol Drinking Clinical Trials and Supportive Activities Placebo Article 03 medical and health sciences Young Adult Double-Blind Method Dopamine Clinical Research mental disorders medicine Humans Adverse effect Catechol-O-methyl transferase Tolcapone business.industry Psychology and Cognitive Sciences Evaluation of treatments and therapeutic interventions Catechol O-Methyltransferase Inhibitors medicine.disease COMT 030227 psychiatry Brain Disorders Good Health and Well Being Impulsive Behavior business 030217 neurology & neurosurgery Decision-making |
Zdroj: | Psychopharmacology (Berl) Psychopharmacology, vol 237, iss 10 |
ISSN: | 1432-2072 |
Popis: | RationaleIndividuals suffering from alcohol use disorder (AUD) demonstrate difficulty with decision-making and impulsivity that may be associated with impaired frontal cortical function. Therapeutics that enhance frontal dopamine tone could decrease impulsivity and in turn reduce alcohol consumption in individuals with AUD.ObjectivesTo determine if the catechol-O-methyltransferase (COMT) inhibitor tolcapone can attenuate alcohol consumption in individuals with AUD and whether this attenuation correlates with tolcapone-induced changes in laboratory-based decision-making tasks.MethodsWe used daily self-report and a novel group laboratory bar task to assess the effects of randomized double-blind crossover administration of tolcapone (100mg TID for 5days) on alcohol consumption and laboratory tasks assessing impulsivity in 55 non-treatment-seeking subjects with AUD.ResultsTolcapone significantly reduced self-reported alcohol consumption (t (54) = 2.05, p = 0.045). The effects of tolcapone on drinking significantly correlated with changes in impulsive decision-making, such that subjects with the greatest decrease in impulsive choice on tolcapone also reported the greatest decrease in alcohol consumption (r (45) = 0.40, p = 0.0053). We did not see effects of tolcapone on laboratory bar consumption. Adverse event (AE) reporting was low, with no significant difference in frequency or severity of AEs on tolcapone versus placebo.ConclusionsThese data demonstrate that COMT inhibitors such as tolcapone may be useful therapeutics for AUD.Trial registrationClinicalTrials.gov Identifier: NCT02740582. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |